Zyversa Therapeutics Stock Analysis
| ZVSA Stock | 0.24 0.10 71.43% |
ZyVersa Therapeutics is undervalued with Real Value of 5.1 and Target Price of 20.0. The main objective of ZyVersa Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what ZyVersa Therapeutics is worth, separate from its market price. There are two main types of ZyVersa Therapeutics' stock analysis: fundamental analysis and technical analysis.
The ZyVersa Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and ZyVersa Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. ZyVersa Stock Analysis Notes
The company has Price to Book (P/B) ratio of 0.09. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. ZyVersa Therapeutics recorded a loss per share of 4.68. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 26th of April 2024. For more information please call the company at (754) 231-1688 or visit https://www.zyversa.com.ZyVersa Therapeutics Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. ZyVersa Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding ZyVersa Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| ZyVersa Therapeutics generated a negative expected return over the last 90 days | |
| ZyVersa Therapeutics has high historical volatility and very poor performance | |
| ZyVersa Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (9.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ZyVersa Therapeutics generates negative cash flow from operations | |
| ZyVersa Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate ... |
ZyVersa Therapeutics Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ZyVersa Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ZyVersa Largest EPS Surprises
Earnings surprises can significantly impact ZyVersa Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.16 | -0.09 | 0.07 | 43 | ||
2025-05-12 | 2025-03-31 | -0.4 | -0.73 | -0.33 | 82 | ||
2024-08-12 | 2024-06-30 | -3.75 | -3.31 | 0.44 | 11 |
ZyVersa Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 707.14 K.ZyVersa Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | -4.8 K | -4.6 K | |
| Return On Capital Employed | (975.31) | (926.55) | |
| Return On Assets | (456.98) | (434.13) | |
| Return On Equity | (1.11) | (1.16) |
Management Efficiency
ZyVersa Therapeutics has return on total asset (ROA) of (0.2479) % which means that it has lost $0.2479 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9139) %, meaning that it created substantial loss on money invested by shareholders. ZyVersa Therapeutics' management efficiency ratios could be used to measure how well ZyVersa Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -4,582. The current year's Return On Capital Employed is expected to grow to -926.55. At present, ZyVersa Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 33.1 M, whereas Net Tangible Assets are forecasted to decline to (11.6 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.67 | 7.29 | |
| Tangible Book Value Per Share | (9.13) | (9.58) | |
| Enterprise Value | -407.4 K | -387.1 K |
Leadership at ZyVersa Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 23rd of July, ZyVersa Therapeutics maintains the Mean Deviation of 6.24, standard deviation of 10.3, and Market Risk Adjusted Performance of (5.57). Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of ZyVersa Therapeutics, as well as the relationship between them.ZyVersa Therapeutics Price Movement Analysis
The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to ZyVersa Therapeutics price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.
ZyVersa Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ZyVersa Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ZyVersa Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ZyVersa Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ZyVersa Therapeutics Outstanding Bonds
ZyVersa Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ZyVersa Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ZyVersa bonds can be classified according to their maturity, which is the date when ZyVersa Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US98981BAA08 Corp BondUS98981BAA08 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| US98980BAA17 Corp BondUS98980BAA17 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
ZyVersa Therapeutics Predictive Daily Indicators
ZyVersa Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ZyVersa Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ZyVersa Therapeutics Forecast Models
ZyVersa Therapeutics' time-series forecasting models are one of many ZyVersa Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ZyVersa Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About ZyVersa Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how ZyVersa Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling ZyVersa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as ZyVersa Therapeutics. By using and applying ZyVersa Stock analysis, traders can create a robust methodology for identifying ZyVersa entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current ZyVersa Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ZyVersa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ZyVersa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 20.0 | Strong Buy | 1 | Odds |
Most ZyVersa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand ZyVersa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of ZyVersa Therapeutics, talking to its executives and customers, or listening to ZyVersa conference calls.
ZyVersa Stock Analysis Indicators
ZyVersa Therapeutics stock analysis indicators help investors evaluate how ZyVersa Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading ZyVersa Therapeutics shares will generate the highest return on investment. By understating and applying ZyVersa Therapeutics stock analysis, traders can identify ZyVersa Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 3.1 M | |
| Common Stock Shares Outstanding | 1.1 M | |
| Total Stockholder Equity | 8.5 B | |
| Tax Provision | 6745.00 | |
| Cash And Short Term Investments | 1.5 M | |
| Cash | 1.5 M | |
| Accounts Payable | 9.3 M | |
| Net Debt | -1.5 M | |
| 50 Day M A | 0.578 | |
| Total Current Liabilities | 11.2 M | |
| Non Current Assets Total | 18.9 M | |
| Non Currrent Assets Other | 235.7 K | |
| Stock Based Compensation | 705.6 K |
Complementary Tools for ZyVersa Stock analysis
When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |